Cellectis signs agreement with Harvard Apparatus for electroporation-based instruments Cellectis.

We are delighted to utilize Harvard Apparatus on the distribution of the very efficient technology , declared Dirk Pollet, Chief Business Officer for Cellectis. This offer provides Harvard Apparatus with an excellent new products, while producing a robust revenue stream for Cellectis. Furthermore, it allows the technology to be made open to the extensive analysis community to explore its potential. Chane Graziano, CEO of Harvard Bioscience, commented, This license significantly expands the cell biology research product line provided by Harvard Apparatus beneath the Warner Instruments and BTX brands.Producers in the United States label the quantity of heparin contained in their products based on USP standards. The changes followed by the USP for the heparin unit dose match the World Health Organization’s International Regular unit dose definition that has been in use in Europe for several years. The revised USP reference standard and unit description for heparin is approximately ten % less potent compared to the former USP unit. Related StoriesAmputation is not wound healingMelatonin and the circadian rhythm: an interview with Professor Kennaway, University of AdelaideBetter visualization in complex reconstructive surgery with ZEISS Opmi Pentero 800 surgical microscopeA device is the measure of a drug’s activity in the body.